The positive impact of adjuvants on vaccination can be functional and practical. A handful of adjuvants are currently licensed for human vaccination, and a number of new adjuvants have reached advanced development stages. However, access to these and other adjuvants is limited. Presented at the 2012 Conference on Modern Vaccines Adjuvants and Delivery Systems, this poster outlines PATH’s work to expand access to proprietary and non-proprietary adjuvants as well as relevant formulations technologies to facilitate their successful exploration and use by product development partnerships and developing-country vaccine manufacturers.

Author(s): Blum J, Chen D, Cummings R

Published: 2012

Resource types: PATH resource; Presentation

Diseases: Not disease/vaccine specific

Topics: Presentation and packaging

Regions: Global